Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

60%

3 of 5 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 1

4(80.0%)

Phase 3

1(20.0%)

5Total

Phase 1(4)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT05076838Phase 1Completed

Pharmacokinetics Study of VALTOCO® in Pediatric Subjects With Epilepsy

Role: lead

NCT06600477Phase 1Completed

A Study of Olanzapine After Intranasal and Intramuscular Administration

Role: lead

NCT02721069Phase 3Completed

Repeat Dose Safety Study of NRL-1 in Epilepsy Subjects

Role: lead

NCT02724423Phase 1Completed

Repeat-Dose Pharmacokinetics Study of NRL-1 in Epilepsy Subjects

Role: lead

NCT01364558Phase 1Completed

A Study of Diazepam After Intranasal and Intravenous Administration to Healthy Volunteers

Role: collaborator

All 5 trials loaded